GDC-6599
Drug Hunter
SEPTEMBER 18, 2023
I trial showed it was well-tolerated, in contrast to prior molecules. IIa trial, GDC-6599 will be evaluated for its efficacy and safety in patients with chronic cough ( persistent cough > 8 weeks ). request a trial You don’t have time to read everything, but you can’t afford to fall behind. already a member?
Let's personalize your content